HistoGeneX is now CellCarta Learn More

MONTREAL, Canada, January 26, 2021– Caprion-HistoGeneX, a leading global provider of specialized precision medicine laboratory services to the biopharmaceutical industry, is pleased to announce its new corporate name, CellCarta, and brand identity.

More

Thank you:

For your belief in us.
You trusted our teams and our systems in a year that was particularly disjointed. That means a lot to us. Our US, European, and now China teams all look forward to earn the right to be your global partner.

For teaching us.
You have made us better scientifically and operationally. We treasure our scientific discourses with you and will continue to become more efficient and foster simplicity.

For keeping it real. Keeping it fun.
Your commitment and straight talk really help us get things done. Thanks for the moments of enjoyment along the way.

For reminding us of the patients we serve.
We celebrate your successes. We admire your persistence. Through both, we care for our patients.

From us, to you:
We thank you whole-heartedly and wish you a wonderful New Year.

More

Caprion-HistoGeneX Expands its Histological Biomarker Franchise by Joining Forces with Mosaic Laboratories

More

Caprion-HistoGeneX Acquires Clinical Logistics Inc., a Virtual Central Specimen Management CRO, and Expands its Support of Clinical Trials Specimen Logistics

More

A CRO Laboratory with a Global Presence
For Expertise Where You Need It

We are expanding our presence worldwide to better serve our clients and to support global clinical trials. All our locations are dedicated to quality science and strong regulatory compliance. Our platforms and systems are standardized globally and follow well-defined processes to safeguard your data. In addition to our commitment to superior sample management, you can count on our local scientific teams at every site for guidance on assay development and sample processing.

More

Discussions on COVID-19 immune responses, including responses in early vaccine clinical studies, have focused largely on antibody responses. However, recent data indicate that the cellular immune response also plays an important role and should be considered when evaluating the immune response. Assessing T-cell responses can provide critical information about vaccine responses and the development and persistence of protective immunity against SARS-CoV-2 that will be critical in the fight against COVID-19.

Join Scott Gottlieb, MD, 23rd Commissioner of the FDA, and James E. Rothman, PhD, Nobel Laureate, both members of Caprion-HistoGeneX’s scientific advisory board, as well as Eustache Paramithiotis, PhD, our VP of Research & Development, who, during this webinar, will help you recognize the importance of cell immunity in COVID-19-related vaccine development.

More

China is ready for Flow Cytometry and IHC!

It's appropriate to begin this newsletter with a "thank you." We are grateful for your encouragement and support for our endeavor in Jining, China. Our laboratory is operational for IHC and flow cytometry. Both IHC and flow cytometry clinical trial patient specimens arrive this month. Our highly experienced Chinese team is in place and we have completed numerous process milestones (e.g. HGRAC, Biosafety level 2 certification, import permits, etc.). For your Chinese clinical trial projects, you will enjoy the seamless workflow from proposal generation to data reporting supported by our local Chinese team. Thank you for committing your clinical trials into our hands. We are honored to have your trust and enthusiasm.

More